Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Asahimas Flat Glass Tbk (AMFG) vs Dharma Polimetal Tbk. (DRMA) Price & Performance

Asahimas Flat Glass TbkTrade
Dharma Polimetal Tbk.Trade

Price performance (Past 24H)

Key statistics

Asahimas Flat Glass Tbk vs Dharma Polimetal Tbk. — how do they compare? Asahimas Flat Glass Tbk trades at Rp3,330 (market cap 1.44T, 5.3K 24h volume), while Dharma Polimetal Tbk. trades at Rp985 (market cap 4.64T, 531.1K 24h volume). The key difference: Dharma Polimetal Tbk. is far larger — about 3.2× Asahimas Flat Glass Tbk's market cap, and Dharma Polimetal Tbk. is more actively traded (531.1K versus 5.3K). Which is the better fit depends on your goals.

AMFGDRMA
Market Cap
1.44T4.64T
Volume
5.3K531.1K
Lot
535.31K
Turnover
17.62M523.32M
Average Price
3,323.77985.35
Value
17.62M523.32M
Indicative Equilibrium Price
985
Indicative Equilibrium Volume
125

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMFG
View details
DRMA
View details

About Asahimas Flat Glass Tbk

PT. Asahimas Flat Glass Tbk (The Company) was established within the foreign capital investment framework of Law No. 1 of 1967 and Law No. 11 of 1970, by deed of notary public Koerniatini Karim dated 7 October 1971 No. 4, as amended by deed of the same notary dated 6 January 1972 No. 9; these deeds were approved by the Minister of Justice under No. J.A.5/5/19 dated 17 January 1972. The Company is a joint venture between Asahi Glass of Japan and the Rodamas Group of Indonesia. Asahi Glass is one of the leading glass producers in the world.

Read more on AMFG

About Dharma Polimetal Tbk.

PT Dharma Polimetal Tbk (“the Company”) was established in the Republic of Indonesia on 27 March based on Notarial deed No. 74 of Rukmasanti Hardjasatya, S.H. The Company begin opertions on year 1989 and commenced its commercial activities since 1990. The Company’s Majority shareholder is PT Dharma Inti Anugerah, established in Republic Indonesia on 20 November 2003.

Read more on DRMA